Swiss regulator gives green light to first drug to prevent Covid-19
The drug is currently only approved for use to prevent Covid-19 among people who don't receive enough protection from vaccines.
Copyright 2020 The Associated Press. All Rights Reserved
Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis drug approved by the Swiss medical regulator.
This content was published on
2 minutes
Keystone-SDA/jdp
Русский
ru
Швейцарский регулятор одобрил препарат для профилактики Covid-19
This authorisation means that the drug, which is administered as an injection, can now be reimbursed by the federal government or health insurance under certain conditions. Evusheld, which is an antibody combination of Tixagevimab and Cilgavimab, is intended for people 12 years and older who aren’t able to build up sufficient immune defenses against Covid-19 from vaccines.
The federal government has already signed contracts with AstraZeneca’s Swiss subsidiary to procure the Covid-19 drug starting with 5,000 doses, according to Keystone-SDA.
Evusheld is authorised for use for Covid-19 prevention in the United States (emergency use), Japan, the European Union and several other countries.
In the UK, where AstraZeneca has its headquarters, officials recently saidExternal link they will not purchase the drug citing “insufficient data” on the duration of protection it provides against the dominant variant Omicron and its subvariants.
On Friday, the EU extended its recommendation for the drug so that it can also be used as a treatment. Swissmedic is still reviewing Evusheld for use as a treatment. However, Swiss Covid regulations allow for the drug to be used to treat Covid-19 patients under certain conditions as the company’s application is being reviewed.
Other treatments
On Friday, the World Health Organization rescinded recommendations for two Covid-19 antibody therapies, stating that new variants have rendered them obsolete.
The two therapies, sotrovimab and casirivimab-imdevimab, were designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells.
GSK and partner Vir Biotechnology’s sotrovimab was pulled off the US market by the Food and Drug Administration (FDA) in April.
In January, the FDA also revised its stance on Casirivimab-imdevimab, which is sold under the name REGEN-COV. It limited the use of the drug sold by Swiss firm Roche and US firm Regeneron to a smaller group of patients, citing that it is less effective against the Omicron variant.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Swiss businessman gets prison term for asbestos deaths
This content was published on
Stephan Schmidheiny has been sentenced to 9 years and 6 months in prison by the Turin Court of Appeal in a case against the Eternit executive over deaths linked to asbestos exposure in Italy.
This content was published on
Swiss imports and exports reached new heights in the first quarter, driven by the chemicals and pharmaceuticals sectors. Shipments to the US rose sharply.
Italian in Switzerland accused of being Calabrian mafia henchman
This content was published on
The Office of the Attorney General of Switzerland has charged an Italian resident of the Anello-Fruci 'Ndrangheta clan in the canton of Aargau.
Swiss CFOs have a pessimistic outlook due to trade wars
This content was published on
In the wake of the trade wars launched by US President Donald Trump, Swiss companies are assessing the future much more pessimistically.
Swiss parcel bomber had links to military and intelligence services
This content was published on
The 61-year-old man who admitted to being Patek Philippe's blackmailer in Geneva had connections in the police and the army.
Explainer: How ready is Switzerland for a new wave of Covid-19?
This content was published on
Covid-19 cases are on the rise again, sparking renewed talk of vaccination and a possible return to social distancing in the autumn.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.